At the outset of our efforts, we noted that the polyketide
skeleton arises biosynthetically from reiterative couplings of
simple malonate building blocks, with tailoring reactions
generating most of the structural diversity, primarily through
variations in oxidation state and stereochemical configura-
tion.8 We envisioned a conceptually related synthetic ap-
proach in which simple precursors are transformed stereo-
selectively to a variety of polyketide structures through
formal alterations in oxidation state, with each synthetic
intermediate also representing a desired polyketide fragment.
Such an approach can be considered “biomimetic” under
Breslow’s original broad definition.9 Importantly, in contrast
to polyketide total synthesis, in which a variety of synthetic
approaches can be interchanged as necessary, diversity-
oriented synthesis requires that these various polyketide
motifs be accessed in a unified, systematic fashion.
Scheme 1. Unified Strategy for the Synthesis of 6-Carbon
Polyketide Fragments Having Skeletal and Stereochemical
Diversity (4-9)a
Thus, we formulated the general synthetic strategy outlined
in Scheme 1, using propargylic alcohols 3 as versatile
synthetic precursors10 that could be transformed to a variety
of polyketide structures. These key intermediates could be
generated from R-alkoxycarbonyl compounds 1 and alkynes
2, potentially bearing R1 and R3 substituents. Terminal benzyl
ether and dimethyl acetal groups were selected as function-
alities that are directly compatible with biological assays,11
and are also potential handles for further functionalization.
Subsequent reductive and oxidative transformations would
then provide six different polyketide skeletal motifs: allylic
alcohols (4), enones (5), epoxyols (6), epoxyketones (7),
1,3-diols (8), and â-hydroxyketones (9). R2 substituents could
potentially be installed in conjunction with any of the formal
reduction steps and the 1,3-diols 8 could be accessed from
a R1, R2, R3 ) H or Me; (*) ) site of stereochemical diversity.
either epoxyols 6 or â-hydroxyketones 9. Alcohol deoxy-
genation reactions can also be anticipated to provide corre-
sponding deoxypolyketide fragments (not shown).
To begin exploring this concept, we synthesized propar-
gylic alcohols 3 (R3 ) H) by coupling of Weinreb amides 1
(R1 ) H or Me, X ) N[Me]OMe) and 3-butynal dimethyl
acetal (2, R3 ) H), followed by stereoselective alkynone
reduction.12,13 We then investigated transformation of the key
intermediates 3 to various polyketide motifs (Scheme 2).
With a view toward future solid-phase implementations, we
sought homogeneous reaction conditions for stereospecific
alkyne reduction to Z-allylic alcohols 10. Gratifyingly, Sato’s
titanocene-catalyzed hydromagnesiation reaction provided an
effective solution.14 Alkyne reduction with Red-Al also
provided the complementary E-allylic alcohols 11.15
(5) (a) Lee, D.; Sello, J. K.; Schreiber, S. L. J. Am. Chem. Soc. 1999,
121, 10648-10649. (b) Lee, D.; Sello, J. K.; Schreiber, S. L. Org. Lett.
2000, 2, 709-712. (c) Kwon, O.; Park, S. B.; Schreiber, S. L. J. Am. Chem.
Soc. 2002, 124, 13402-13404. (d) Ding, S.; Gray, N. S.; Wu, X.; Ding,
Q.; Schultz, P. G. J. Am. Chem. Soc. 2002, 124, 1594-1596. (e)
Couladouros, E. A.; Strongilos, A. T. Angew. Chem., Int. Ed. 2002, 41,
3677-3680. (f) Burke, M. D.; Berger, E. M.; Schreiber, S. L. Science 2003,
302, 613-618. (g) Burke, M. D.; Berger, E. M.; Schreiber, S. L. J. Am.
Chem. Soc. 2004, 126, 14095-14104. (h) Taylor, S. J.; Taylor, A. M.;
Schreiber, S. L. Angew. Chem., Int. Ed. 2004, 43, 1681-1685. (i) Oguri,
H.; Schreiber, S. L. Org. Lett. 2005, 7, 47-50. (j) Kumagai, N.; Muncipinto,
G.; Schreiber, S. L. Angew. Chem., Int. Ed. 2006, 45, 3635-3638. (k)
Yeager, A. R.; Min, G. K.; Porco, J. A., Jr.; Schaus, S. E. Org. Lett. 2006,
8, 5065-5068.
We next sought to oxidize allylic alcohols 10 and 11 to
epoxyols 12 and 13, respectively, using stereoselective
epoxidation reactions. As hoped, syn epoxidation of Z-allylic
alcohols 10 with m-CPBA provided the cis,syn-epoxyols 12.16
Conversely, anti epoxidation of E-allylic alcohols 11a and
anti-11b under matched Sharpless conditions17 provided the
trans,anti-epoxyols 13, although syn-11b proved unreactive
in this case. Interestingly, however, syn-11b was amenable
to syn epoxidation with m-CPBA in unusually high stereo-
selectivity, providing one of the desired C2 epimeric ep-
oxyols directly (not shown).13,16 Alcohol inversions using
Mitsunobu or oxidation/re-reduction protocols then afforded
(6) (a) Sutherlin, D. P.; Armstrong, R. W. J. Am. Chem. Soc. 1996, 118,
9802-9803. (b) Annis, D. A.; Helluin, O.; Jacobsen, E. N. Angew. Chem.,
Int. Ed. 1998, 37, 1907-1909. (c) Harrison, B. A.; Gierasch, T. M.; Neilan,
C.; Pasternak, G. W.; Verdine, G. L. J. Am. Chem. Soc. 2002, 124, 13352-
13353. (d) Kim, Y.-k.; Arai, M. A.; Arai, T.; Lamenzo, J. O.; Dean, E. F.,
III; Patterson, N.; Clemons, P. A.; Schreiber, S. L. J. Am. Chem. Soc. 2004,
126, 14740-14745. (e) Potuzak, J. S.; Moilanen, S. B.; Tan, D. S. J. Am.
Chem. Soc. 2005, 127, 13796-13797. (f) Moilanen, S. B.; Potuzak, J. S.;
Tan, D. S. J. Am. Chem. Soc. 2006, 128, 1792-1793.
(7) (a) Tan, D. S. Nat. Chem. Biol. 2005, 1, 74-84. (b) Burke, M. D.;
Schreiber, S. L. Angew. Chem., Int. Ed. 2004, 43, 46-58. (c) Schreiber, S.
L. Science 2000, 287, 1964-1969.
(8) Fischbach, M. A.; Walsh, C. T. Chem. ReV. 2006, 106, 3468-3496.
(9) Breslow, R. Chem. Soc. ReV. 1972, 1, 553-580.
(10) The potential utility of propargylic alcohols in diversity-oriented
synthesis has been noted previously: Weber, L. Curr. Opin. Chem. Biol.
2000, 4, 295-302.
(12) Initial attempts to access 3a directly by various asymmetric alkyne
additions to the corresponding aldehydes (reviewed in: Pu, L. Tetrahedron
2003, 59, 9873-9886.) suffered from poor enantioselectivity.
(13) See the Supporting Information for full details.
(11) For examples of stable, biologically active dimethyl acetals, see:
(a) Cho, W.-J.; Kim, E.-K.; Park, I. Y.; Jeong, E. Y.; Kim, T. S.; Le, T. N.;
Kim, D.-D.; Lee, E.-S. Bioorg. Med. Chem. 2002, 10, 2953-2961. (b)
Springer, R. H.; Scholten, M. B.; O’Brien, D. E.; Novinson, T.; Miller, J.
P.; Robins, R. K. J. Med. Chem. 1982, 25, 235-242. (c) Kim, C. D.; Kim,
H. H.; Kim, Y. K.; Kwak, Y. K.; Kim, S.-O.; Yoo, S.-E.; Hong, K. W. J.
Pharmacol. Exp. Ther. 2001, 296, 1085-1090.
(14) Sato, F.; Ishikawa, H.; Watanabe, H.; Miyake, T.; Sato, M. J. Chem.
Soc., Chem. Commun. 1981, 718-720.
(15) Chan, K.-K.; Cohen, N.; De Noble, J. P.; Specian, A. C., Jr.; Saucy,
G. J. Org. Chem. 1976, 41, 3497-3505.
(16) Adam, W.; Wirth, T. Acc. Chem. Res. 1999, 32, 703-710.
(17) Katsuki, T.; Martin, V. S. Org. React. 1996, 48, 1-299.
1896
Org. Lett., Vol. 9, No. 10, 2007